Skip to main
PYPD

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid is well-positioned for success with a proven drug delivery technology, a strong pipeline of products, and a strategic partnership with Azurity Pharmaceuticals to support commercialization efforts. The company has also secured a significant amount of upfront and near-term payments, as well as potential milestone payments, which reduces financing risk and provides runway into profitability in 2029. With a strong management team and major advancements on the regulatory and commercial fronts, PolyPid has the potential to drive significant value for its shareholders in the long term.

Bears say

PolyPid is overvalued as a single asset company with a current market value of $177 million, given that their sole product candidate D-PLEX100 is still in clinical stages and faces competition in the anti-infective market. Although the company may receive significant upfront and milestone payments, their tiered royalty structure may not generate significant revenue in the near term and the success of their broader pipeline approach remains uncertain. Additionally, the company's financial stability may be at risk if they are unable to secure a commercial partnership for D-PLEX100.

PolyPid (PYPD) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 3 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.